CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Patient Status EngineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D019337 Hematologic Neoplasms NIH 0.38

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001909 Leukemia HPO 0.30

There is one clinical trial.

Clinical Trials


1 Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.

Since emerging in December 2019, coronavirus disease 2019 (Covid-19) has developed into an unprecedented global pandemic. The causative pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to cause a wide range of clinical syndromes, from fever, dyspnoea and cough to respiratory failure and cardiac injury necessitating critical care support. A number of patients have a more indolent clinical course and can be safely managed in the community. Characterising the clinical course of Covid-19 infection in the oncology population and distinguishing this from other acute oncology presentations which can mimic Covid-19 is a key unmet research need. Current standard of care for monitoring patients at high risk of chemotherapy associated neutropenic sepsis involves asking them to contact their cancer centre when they feel unwell or develop a fever. No standard of care for monitoring ambulatory Covid-19 patients has yet been established. We hypothesise that using wearable biosensors to detect patients who exhibit 'red flags' for sepsis or deterioration due to Covid-19 may allow earlier assessment and intervention. There is no current evidence for wearable biosensors in ambulatory patients receiving chemotherapy, and there is no existing research into this proposed use of biosensors in patients with suspected or confirmed Covid-19 infection. In order to justify performing a randomised controlled study comparing standard of care with biosensor driven monitoring it is important to establish the tolerability and validity of these devices. We aim to collect patient reported outcome measures (PROMs) on tolerability and assess the reliability of data transmission to a central data collection server. We will also perform an initial analysis of physiological data and correlation with clinical events

NCT04397705 COVID Oncology Haematological Malignancy Device: Patient Status Engine
MeSH:Hematologic Neoplasms
HPO:Hematological neoplasm Leukemia

Primary Outcomes

Description: Percentage of patients who choose to stop wearing the devices before they have completed the study

Measure: Device Tolerability (Attrition)

Time: Three weeks

Description: Correlation of sensor collected data with clinical episodes of infection. Sensor collected data includes heart rate, respiratory rate and temperature.

Measure: Correlation of physiological data with clinical events

Time: Over three weeks of patients wearing devices

Secondary Outcomes

Description: Percentage of participants who answer 'agree' or 'strongly agree' on a five point Likert scale to the statement 'I would be happy to wear the sensors again for the next three weeks'. This statement is included in the questionnaires completed after three weeks of wearing the device.

Measure: Device Tolerability (Questionnaire)

Time: Questionnaire at three weeks

Description: Device tolerability as assessed by semi-structured interviews.

Measure: Device Tolerability (Semi-structured interviews)

Time: One to four weeks after completion of wearing the device

Description: Reliable data transmission to central hospital system expressed as a percentage of total data points collected out of target data points collected.

Measure: Reliability of data transmission

Time: Over three weeks of patients wearing devices


Related HPO nodes (Using clinical trials)


HP:0004377: Hematological neoplasm
Genes 351
CHEK2 FANCE CBL TERT ATRX TERT RPS24 BIRC3 GATA1 STS JAK2 FANCL POT1 NOP10 TERT GATA2 RFWD3 MLH1 TCF4 LIG4 NPM1 RARA CD19 SH3GL1 CASP10 PDGFRA RPL5 BRIP1 ERBB3 RUNX1 KRAS PIGL CD81 SAMD9 THPO DYNC2LI1 RPS26 RAG2 WRAP53 CBL GFI1B STAT3 ABL1 LPP ATM TP53 IGH NRAS RPL26 RPS29 CALR ASXL1 CEBPA MALT1 ELANE CD19 TET2 NUP214 MSH2 CCND1 HAX1 SMARCD2 MYD88 EVC RAD54B RUNX1 FANCF SAMHD1 TRIP13 TNFRSF13B RUNX1 TP53 RPS10 CALR FLT3 BCL10 NRAS SETBP1 MSH2 TNFRSF13C SH2B3 FANCC BCL6 BLM CD28 LIG4 MCM4 FANCG GATA2 MYD88 GBA BCL2 GINS1 TET2 IL7R MYSM1 SLX4 KIT NBN RASGRP1 RB1 TINF2 RECQL4 FASLG PRF1 BRD4 TREX1 THPO SMPD1 FANCI NBEAL2 BUB3 ATM PDGFRB FAS FANCD2 RPS28 ZAP70 FANCA BAX LIG4 RPL11 LYST ADA CHIC2 POLE XIAP KRAS RTEL1 EVC2 XRCC2 SCN10A MPL CTLA4 ASXL1 MDM2 SAMD9L GATA2 RNASEH2B CBL JAK2 PNP UBE2T CBFB ARHGAP26 SCN11A MPL TINF2 F13A1 DCLRE1C SRP72 BCR SBDS ADA ICOS NAGS FANCB GNB1 TAL1 PIGA NUP214 TYROBP GFI1 RAD51 BCL10 TREM2 ICOS CEP57 MLH1 IGH PICALM FANCM ERCC4 FANCD2 RPS15A FANCE PIK3R1 ELANE WIPF1 IL2RG GATA1 SRP54 RAF1 LIG4 NFKB1 PTPN11 XRCC4 SRP54 TET2 TET2 PTEN EP300 CASP10 DNASE1L3 PTPN11 MS4A1 GATA2 RASGRP1 NUTM1 NTHL1 ETV6 TET2 NPM1 PIGL GFI1 RPS14 BCL10 WAS RPL18 SH2B3 RMRP SRSF2 DNMT3A DNAJC21 RPS27 RPS7 MPL FOXP1 DNMT3A CALR ASXL1 MPL TNFRSF13C TSR2 RUNX1 DKC1 APC ADAR RAD51C BRCA2 GLI1 IFIH1 SCN9A CDKN2A SH2D1A KLHDC8B NSUN2 CREBBP PGM3 SRP54 SBDS SH2B3 DNAJC21 CHD7 MPL BCR GATA2 BRCA1 BUB1B TERC CALR TNFRSF13B CD28 SAMD9L AAGAB BCR TP53 TCIRG1 ADA2 HSPA9 PIK3CA SRSF2 RNF43 TERT CR2 COL14A1 IGH RMRP FANCG IL2RG JAK2 KIF11 FLT3 JAK2 MAD2L2 FANCC RPS17 PARN NUMA1 RAD54L MSH6 RPL35 BRAF RNASEH2C CD70 SF3B1 MSH6 DDX41 TERC RECQL4 PMS2 RPL35A CCND1 BUB1 SF3B1 TERC TET2 RFWD3 CTLA4 MYC DNAJC21 TNFSF12 MAGT1 BLM FANCA KIT ITK RPL31 MLLT10 RPL15 RNASEH2A CR2 NHP2 TAL2 RPS14 NBN CD27 TCF4 NFKB2 RPS19 TNFSF12 HLA-DRB1 FAS RHOH NF1 ABL1 USB1 BUB1B NBN TET2 LIG4 PRKCD CTC1 JAK2 RPL27 PRKCD RPS19 TNFRSF1B BRCA2 DKC1 PALB2 F13B ATRX RAG1 TP63 EFL1 TNFRSF1B TET2 TET2 JAK2 KRAS
Protein Mutations 0
SNP 0